Attachment and Prognostic Factor: the Implicit Approach (AIA)

June 3, 2025 updated by: Centre Hospitalier Henri Laborit

Place of Attachment as a Post-weaning Prognostic Factor: Interest of the Implicit Approach

This is a prospective longitudinal study aimed at better understanding the determinants of the prognosis of patients with substance dependence.

5 visits are planned during the study :

  • the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online
  • 4 telephone interviews for follow-up by investigator.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients with a use-related disorder weaning for a substance, supported within the addictology sector of Henri Laborit Hospital

Description

Inclusion Criteria:

  • Patients between 18 and 65 years old
  • Patients with a use-related disorder as defined by DSM5
  • Patients weaning for a substance, supported within the addictology sector of Henri Laborit Hospital
  • Having expressed non-opposition to participating in the study after receiving written information.

Exclusion Criteria:

  • Person who cannot read or write
  • Simultaneous participation in a therapeutic trial involving oxytocin
  • Patients protected by law
  • Patients who do not have French as their native language
  • Patients who, in the opinion of the investigator, are unable to complete the questionnaires

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients with a use-related disorder weaning for a substance
Behavioral: Questionnaires

5 visits are planned during the study :

  • the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online
  • 4 telephone interviews for follow-up by investigator

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implicit attachment and onsumption
Time Frame: 12 months
Assessment of the link between implicit attachment and changes in consumption after a 12-month follow-up
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Henri Laborit

Investigators

  • Principal Investigator: Wilfried SERRA, Dr, Centre Hospitalier Henri Laborit

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2028

Study Completion (Estimated)

September 1, 2028

Study Registration Dates

First Submitted

June 29, 2021

First Submitted That Met QC Criteria

June 29, 2021

First Posted (Actual)

July 8, 2021

Study Record Updates

Last Update Posted (Estimated)

June 5, 2025

Last Update Submitted That Met QC Criteria

June 3, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2021-A00432-39

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dependence Addictive

Clinical Trials on Questionnaires

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe